Chlorthalidone no better than hydrochlorothiazide for HTN

March 20, 2013
Chlorthalidone no better than hydrochlorothiazide for HTN
For older adults with hypertension, chlorthalidone is not associated with fewer adverse cardiovascular events or death, but correlates with increased hypokalemia compared with hydrochlorothiazide, according to a study published in the March 19 issue of the Annals of Internal Medicine.

(HealthDay)—For older adults with hypertension, chlorthalidone is not associated with fewer adverse cardiovascular events or death, but correlates with increased hypokalemia compared with hydrochlorothiazide, according to a study published in the March 19 issue of the Annals of Internal Medicine.

Irfan A. Dhalla, M.D., from St. Michael's Hospital in Toronto, and colleagues conducted an observational cohort study involving 29,873 individuals aged 66 years or older who were newly treated with chlorthalidone or hydrochlorothiazide and were not hospitalized for , stroke, or myocardial infarction in the prior year. Chlorthalidone recipients (10,384 patients) were matched with up to two hydrochlorothiazide recipients based on age, sex, year of treatment initiation, and .

During up to five years of follow-up, the researchers found that the rate of a composite of death or hospitalization for heart failure, stroke, or was not significantly different between the groups (3.2 events per 100 person-years of follow-up among chlorthalidone recipients versus 3.4 events for hydrochlorothiazide recipients). Hospitalization with hypokalemia (adjusted hazard ratio, 3.06) or hyponatremia (adjusted hazard ratio, 1.68) was significantly more likely in patients treated with chlorthalidone. In post-hoc analyses, hospitalization with hypokalemia was more likely with chlorthalidone in all dose comparisons between the two drugs (12.5, 25, or 50 mg daily) in which a significant association was found.

"In the absence of convincing evidence for the superiority of either chlorthalidone or hydrochlorothiazide, we believe that clinicians who care for older adults should focus primarily on reaching patient-relevant blood pressure goals while being mindful of the risk for electrolyte abnormalities in patients treated with diuretics," write the authors.

One author disclosed to pharmaceutical companies.

Explore further: Sulfonylureas up cardio events versus metformin

More information: Full Text (subscription or payment may be required)

Related Stories

Sulfonylureas up cardio events versus metformin

November 7, 2012
(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of ...

Choice of psoriasis treatment affects CVD event rates

September 27, 2012
(HealthDay)—Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial ...

Metformin cuts cardio events in high-risk type 2 diabetes

January 8, 2013
(HealthDay)—Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.

Clopidogrel after MI less effective in diabetes patients

September 5, 2012
(HealthDay)—Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue of the Journal ...

Combo of diabetes, depression increases post-MI mortality

February 27, 2012
(HealthDay) -- Having both diabetes and depression significantly increases the risk of dying in the years following a heart attack, beyond the increased risk from either condition alone, according to a study published in ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.